Next, we categorized the patients into two groups: significant fibrosis group and non-significant fibrosis group (APRI cutoff value = 0.5) according to the World Health Organization (WHO) “Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection” and found that LAIR-1 expression frequency on total T cells, CD4+ T cells, and CD8+ T cells in the non-significant fibrosis group was significantly higher than that in the significant fibrosis group (p = .0032, p = .0020, and p < .0001, respectively; Figure 6M–O). This evidence concerns the gene LAIR1 and fibrosis.